United Therapeutics Corporation (UTHR)

United Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	2,328	1,936	1,686	1,483	1,449
Revenue Growth (YoY)	20.20%	14.88%	13.63%	2.38%	-11.00%
Cost of Revenue	257.5	151.6	122.5	108.1	117.6
Gross Profit	2,070	1,785	1,563	1,375	1,331
Selling, General & Admin	477.1	482.1	467	423.9	336.2
Research & Development	408	322.9	540.1	357.7	1,183
Operating Expenses	885.1	805	1,007	781.6	1,519
Operating Income	1,185	979.7	555.9	593.6	-187.6
Interest Expense / Income	59.3	32.4	18.6	23.5	44.2
Other Expense / Income	-148.7	-3.3	-56.6	-68.8	-66.8
Pretax Income	1,274	950.6	593.9	638.9	-165
Income Tax	289.5	223.3	118.1	124.1	-60.5
Net Income	984.8	727.3	475.8	514.8	-104.5
Net Income Growth	35.40%	52.86%	-7.58%	-	-
Shares Outstanding (Basic)	47	46	45	44	44
Shares Outstanding (Diluted)	50	49	47	45	44
Shares Change	2.47%	2.54%	6.05%	1.83%	-0.45%
EPS (Basic)	21.04	15.98	10.60	11.65	-2.39
EPS (Diluted)	19.81	15.00	10.06	11.54	-2.39
EPS Growth	32.07%	49.11%	-12.82%	-	-
Free Cash Flow	747.6	663.7	477.4	698.8	-290.3
Free Cash Flow Per Share	15.97	14.59	10.63	15.81	-6.63
Gross Margin	88.94%	92.17%	92.73%	92.71%	91.88%
Operating Margin	50.91%	50.60%	32.98%	40.02%	-12.95%
Profit Margin	42.31%	37.56%	28.23%	34.71%	-7.21%
Free Cash Flow Margin	32.12%	34.28%	28.32%	47.11%	-20.04%
Effective Tax Rate	22.72%	23.49%	19.89%	19.42%	-
EBITDA	1,387	1,034	662.4	712.3	-74.9
EBITDA Margin	59.58%	53.42%	39.30%	48.02%	-5.17%
Depreciation & Amortization	53.2	51.3	49.9	49.9	45.9
EBIT	1,334	983	612.5	662.4	-120.8
EBIT Margin	57.30%	50.77%	36.34%	44.66%	-8.34%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).